

和鉑醫藥 (2142 HK)



上日收市價：11.43 港元

支持位：10.65 港元/ 10.07 港元

阻力位：13.52 港元/ 14.98 港元

技術分析：

價格已確認在 9.46 港元確立了堅實的筑底架構，且在順勢突破後，成功站穩於阻力轉支撐位上方。目前 RSI 正沿著 50 中性平衡線穩步上行，釋放了良好的動能配合信號。這極其利好指數/股價展開持續性的向上延伸行情，而這一年多頭局面的核心前置條件，則是價格需在日線收盤價基礎上死守這一突破點。

預期平均時限：約 2 週

康耐特光學 (2276 HK)



上日收市價：34.90 港元

支持位：30.04 港元/ 26.50 港元

阻力位：38.64 港元/ 39.78 港元

技術分析：

大盤的反彈在前期強阻力位前精準踩下了剎車，並在昨天以一根極其難看的‘看跌吞沒’大陰線直接拉響了調頭反轉的警報。目前這一冲高受阻的走勢也得到了指標的印證——RSI 在 50 多空分水嶺下方已經明顯掉頭向下跌散。隨著空頭在這一關鍵高點附近重新死死掐住了訂單流的脖子，技術面目前的阻力最小方向毫無疑問已經堅定地倒向了空方，后市大概率會直接复制新一轮的破位下行。

預期平均時限：約 2 週

分析員

大中華研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

+852 2236 6799

munhon.tham@uobkh.com

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at the following link:
<https://research-api.uobkayhian.com/assets/disclaimer/0e6d602f-adeb-45f8-9dea-5d5591daae87> or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."